Cognition Therapeutics (CGTX) Change in Account Payables (2020 - 2022)
Cognition Therapeutics (CGTX) posted quarterly Change in Account Payables of -$5.0 million for Q4 2022, down 305.12% year-over-year from $2.4 million in Q4 2021, and down 204.77% quarter-over-quarter from $4.8 million in Q3 2022.
Cognition Therapeutics (CGTX) Change in Account Payables (2020 - 2022) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Change in Account Payables for 3 consecutive years, with -$5.0 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Change in Account Payables fell 305.12% year-over-year to -$5.0 million; the TTM figure through Dec 2022 stood at -$1.1 million (down 150.44% YoY), while the FY2022 annual figure was -$1.1 million, down 150.44% from the prior year.
- Change in Account Payables retreated to -$5.0 million in Q4 2022 per CGTX's latest filing, from $4.8 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.8 million in Q3 2022 and bottomed at -$5.0 million in Q4 2022.
- Historically, Change in Account Payables has averaged $47000.0 across 3 years, with a median of -$533000.0 in 2021.
- On a YoY basis, Change in Account Payables climbed as much as 785.24% in 2022 and fell as far as 305.12% in 2022.
- Cognition Therapeutics' Change in Account Payables stood at -$650000.0 in 2020, then jumped by 475.85% to $2.4 million in 2021, then slumped by 305.12% to -$5.0 million in 2022.
- Business Quant data shows CGTX's Change in Account Payables at -$5.0 million in Q4 2022, $4.8 million in Q3 2022, and -$693000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -5.01 Mn |
| Dec 31, 2022 | -5.01 Mn |
| Sep 30, 2022 | 4.78 Mn |
| Sep 30, 2022 | 4.78 Mn |
| Jun 30, 2022 | -693,000.00 |
| Jun 30, 2022 | -693,000.00 |
| Mar 31, 2022 | -171,000.00 |
| Mar 31, 2022 | -171,000.00 |
| Dec 31, 2021 | 2.44 Mn |
| Dec 31, 2021 | 2.44 Mn |
| Sep 30, 2021 | -698,000.00 |
| Sep 30, 2021 | -698,000.00 |
| Jun 30, 2021 | -533,000.00 |
| Jun 30, 2021 | -533,000.00 |
| Mar 31, 2021 | 953,000.00 |
| Mar 31, 2021 | 953,000.00 |
| Dec 31, 2020 | -650,000.00 |
| Dec 31, 2020 | -650,000.00 |